Leiomyosarcoma - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 129 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leiomyosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Leiomyosarcoma - Pipeline Review, H2 2016', provides an overview of the Leiomyosarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
- The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leiomyosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Leiomyosarcoma - Overview 8
Pipeline Products for Leiomyosarcoma - Comparative Analysis 9
Leiomyosarcoma - Therapeutics under Development by Companies 10
Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Leiomyosarcoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Leiomyosarcoma - Products under Development by Companies 14
Leiomyosarcoma - Products under Investigation by Universities/Institutes 15
Leiomyosarcoma - Companies Involved in Therapeutics Development 16
Advenchen Laboratories, LLC 16
BeiGene, Ltd. 17
Cell Medica Limited 18
Karyopharm Therapeutics, Inc. 19
Merck & Co., Inc. 20
Millennium Pharmaceuticals Inc 21
Mirati Therapeutics Inc. 22
Novartis AG 23
Pfizer Inc. 24
Vicore Pharma AB 25
Leiomyosarcoma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AL-3818 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
axitinib - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BGB-290 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
C-21 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CMD-003 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
everolimus - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
mocetinostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
pazopanib hydrochloride - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
pembrolizumab - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
sapanisertib - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
selinexor - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Leiomyosarcoma - Dormant Projects 126
Leiomyosarcoma - Discontinued Products 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129

List of Tables

Number of Products under Development for Leiomyosarcoma, H2 2016 8
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Leiomyosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 16
Leiomyosarcoma - Pipeline by BeiGene, Ltd., H2 2016 17
Leiomyosarcoma - Pipeline by Cell Medica Limited, H2 2016 18
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 19
Leiomyosarcoma - Pipeline by Merck & Co., Inc., H2 2016 20
Leiomyosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21
Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H2 2016 22
Leiomyosarcoma - Pipeline by Novartis AG, H2 2016 23
Leiomyosarcoma - Pipeline by Pfizer Inc., H2 2016 24
Leiomyosarcoma - Pipeline by Vicore Pharma AB, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Leiomyosarcoma - Dormant Projects, H2 2016 126
Leiomyosarcoma - Discontinued Products, H2 2016 127